Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ELI LILLY AND COMPANY

(LLY)
  Report
Delayed Nyse  -  04:03 2022-11-30 pm EST
371.08 USD   +1.96%
11/30US FDA Cancels Emergency Use Approval For Eli Lilly's COVID-19 Treatment
MT
11/30Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease
PR
11/30FDA pulls U.S. authorization for Eli Lilly's COVID drug bebtelovimab
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Days
:
Hours
:
Minutes
:
Seconds

Eli Lilly Up Over 7%, on Track for Record High Close -- Data Talk

09/28/2022 | 10:20am EST

Eli Lilly and Company (LLY) is currently at $333.80, up $22.70 or 7.3%


--Would be new all-time high (Based on available data back to July 18, 1972)

--On pace for largest percent increase since Dec. 15, 2021, when it rose 10.39%

--Currently up four of the past five days

--Currently up two consecutive days; up 8.55% over this period

--Best two day stretch since the two days ending Dec. 16, 2021, when it rose 11.89%

--Up 10.81% month-to-date; on pace for best month since March 2022, when it rose 14.57%

--Up 20.84% year-to-date

--Up 44.9% from 52 weeks ago (Sept. 29, 2021), when it closed at $230.36

--Would be a new 52-week closing high

--Up 48.45% from its 52-week closing low of $224.85 on Oct. 4, 2021

--Traded as high as $336.66; new all-time intraday high (Based on available data back to July 18, 1972)

--Up 8.22% at today's intraday high; largest intraday percent increase since Dec. 15, 2021, when it rose as much as 10.49%

--Second best performer in the S&P 500 today


All data as of 10:01:13 AM ET


Source: Dow Jones Market Data, FactSet


(END) Dow Jones Newswires

09-28-22 1019ET

All news about ELI LILLY AND COMPANY
11/30US FDA Cancels Emergency Use Approval For Eli Lilly's COVID-19 Treatment
MT
11/30Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptoma..
PR
11/30FDA pulls U.S. authorization for Eli Lilly's COVID drug bebtelovimab
RE
11/30Eli Lilly's Bebtelovimab COVID-19 Drug Reportedly Paused by US FDA
MT
11/30FDA Pauses Authorization for Eli Lilly's Bebtelovimab COVID Drug
MT
11/30Eli Lilly's COVID drug bebtelovimab not currently authorized in U.S., says FDA
RE
11/30Transcript : Eli Lilly and Company Presents at 5th Annual Evercore ISI Health..
CI
11/30Eli Lilly's Buyout Offer Accepted by 81% Akouos Shareholders at Closing
MT
11/29Eli Lilly Earnings, Revenue Set to Grow in 2023 With 'Modest' Impact From New Launches,..
MT
11/29Rare success for Alzheimer's research unlocks hope for future therapies
RE
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Financials (USD)
Sales 2022 28 669 M - -
Net income 2022 6 134 M - -
Net Debt 2022 10 503 M - -
P/E ratio 2022 55,2x
Yield 2022 1,00%
Capitalization 353 B 353 B -
EV / Sales 2022 12,7x
EV / Sales 2023 12,0x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 371,08 $
Average target price 371,23 $
Spread / Average Target 0,04%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Alonzo Weems Senior VP, Chief Ethics & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY31.76%352 592
JOHNSON & JOHNSON4.05%460 384
ABBVIE INC.19.04%279 679
PFIZER, INC.-15.11%277 803
NOVO NORDISK A/S19.71%276 497
MERCK & CO., INC.43.68%275 952